图表改编自Globocan 2020的《全球癌症观察》(Global Cancer Observatory) 我国《原发性肝癌诊疗指南(2022年版)》[2]推荐的肝癌治疗手段主要为外科治疗、消融治疗、经动脉化疗栓塞(TACE)、放射治疗(如钇90[90Y]内放射治疗)、系统抗肿瘤治疗等。 在局...
13. Xia Y, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer. 2022 Apr;10(4):e004656. 14. Zhang W, et alLenvatinib plus anti-PD-1 anti...
然而,中大医学院牵头的一项多中心临床研究与海外医疗机构合作发现,若将选择性体内放射治疗(SIRT)与标准化疗结合,可有效治疗不适合经手术切除的肝内胆管癌,其总存活期中位数可增加至21.6个月。研究结果已在著名医学杂志《Liver Cancer》发表...
7. Vogel A, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Feb;34(2):127-140.
SIRT Therapy for Metastatic Liver Secondary from Primary Breast CancerAbdullah, B. J.Kananathan, R.Goh, K. L.Mehta, J. C.Medical Journal of Malaysia
钇90微球选择性内放射治疗(Y90-SIRT)作为一种肝脏肿瘤局部治疗手段在国际上应用已超过20年。与其他肝脏局部治疗手段不同,Y90-SIRT具有强效缩瘤和增大余肝体积的双重疗效。这一突出优势也让它成为初始不可切除肝细胞癌(Hepatocellular carcinoma, HCC)降期和转化治疗的理想选择。制定合适的治疗策略是实现不可切除HCC通...
然而,中大医学院牵头的一项多中心临床研究与海外医疗机构合作发现,若将选择性体内放射治疗(SIRT)与标准化疗结合,可有效治疗不适合经手术切除的肝内胆管癌,其总存活期中位数可增加至21.6个月。研究结果已在著名医学杂志《Liver Cancer》发表。 1/4人肿瘤缩小 ...
Our in vivo findings suggest that SIRT2-C/EBPβ signaling pathway can be potentially targeted for ALD treatment. Results SIRT2 inversely correlates with ethanol-induced liver injury in patientsTo assess the relevance of hepatic SIRT2 expression to alcoholic liver injury, we analyzed SIRT2 protein ...
For protein stability assay, cells were treated with 100 μg/ml Cycloheximide (CHX, from Sigma) for the indicated time before harvest. Induction of insulin resistance2 Treatment with recombinant mouse TNF-α (4 ng/ml) was initiated with mature adipocytes from day 8 of differentiation. ...
[11] Roosen J, Klaassen NJM, Westlund Gotby LEL, Overduin CG, Verheij M, Konijnenberg MW, Nijsen JFW. To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation the...